Medicina y salud
Disciplina temática
University of Queensland
Brisbane, AustraliaPublicaciones en colaboración con investigadores/as de University of Queensland (29)
2024
-
AI is a viable alternative to high throughput screening: a 318-target study
Scientific Reports, Vol. 14, Núm. 1
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)
Nature
-
Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget’s disease of bone
Annals of the Rheumatic Diseases, Vol. 83, Núm. 4, pp. 529-536
2022
-
Co-infection and ICU-acquired infection in COIVD-19 ICU patients: a secondary analysis of the UNITE-COVID data set
Critical Care, Vol. 26, Núm. 1
-
Correction: Co-infection and ICU-acquired infection in COVID-19 ICU patients: a secondary analysis of the UNITE-COVID data set (Critical Care, (2022), 26, 1, (236), 10.1186/s13054-022-04108-8)
Critical Care
-
IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S385
-
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Blood Advances
-
Whole-genome sequencing reveals host factors underlying critical COVID-19
Nature, Vol. 607, Núm. 7917, pp. 97-103
2021
-
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
BMC Infectious Diseases, Vol. 21, Núm. 1
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Mapping the human genetic architecture of COVID-19
Nature, Vol. 600, Núm. 7889, pp. 472-477
-
Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19
New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802
2020
-
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study
Blood, Vol. 136, Núm. 18, pp. 2038-2050
-
Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis
Journal of Clinical Oncology, Vol. 38, Núm. 28, pp. 3252-3260
-
Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study Cohort
Journal of Bone and Mineral Research, Vol. 35, Núm. 7, pp. 1246-1252
2019
-
Epidemiology of intra-abdominal infection and sepsis in critically ill patients: “AbSeS”, a multinational observational cohort study and ESICM Trials Group Project
Intensive Care Medicine, Vol. 45, Núm. 12, pp. 1703-1717
-
Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations
Clinical Pharmacokinetics, Vol. 58, Núm. 6, pp. 767-780
-
Zoledronate in the prevention of Paget's (ZiPP): Protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone
BMJ Open, Vol. 9, Núm. 9
2018
-
Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: A Mendelian randomization study
International Journal of Epidemiology, Vol. 47, Núm. 2, pp. 450-459